Agilent Technologies Introduces Tools for Next-Generation Genome Engineering


Source: Agilent Technologies, Inc.

SureGuide Kits Represent First Integrated Solution for In-Vitro CRISPR/Cas9 Research

SANTA CLARA, Calif. -- Agilent Technologies Inc. (NYSE: A) today introduced SureGuide, the first in a new series of kits to advance genome editing and synthetic biology.

The complete SureGuide workflow includes a SureGuide Cas9 Nuclease Kit, SureGuide gRNA Synthesis Kit and SureGuide gRNA Control Kit, all designed to work together for any lab interested in quickly enabling next-generation genome engineering. The workflow represents the first integrated solution for in-vitro CRISPR/Cas9 experiments, with gRNA design and gRNA synthesis, and is available as a kit or as individual components.

The SureGuide family of tools will enable in-vitro cloning of large genes or complex DNA mixtures without the limitations imposed by common restriction enzymes or PCR fidelity. With SureGuide, scientists can cleave DNA at single and multiple locations, and rapidly alter target regions with minimal effort. The SureGuide gRNA synthesis kit integrates highly efficient synthesis with an optimized purification step in a streamlined protocol.

'SureGuide provides a simple, integrated tool set designed to expand access to this remarkable technology by making it easier for scientists to integrate CRISPR/Cas9 in their everyday cloning workflows,' said Alessandro Borsatti, senior director of Marketing for Agilent's Diagnostics and Genomics Solutions Group. 'SureGuide enables truly programmable, customizable cloning specificity while improving on the efficiency scientists expect from current nuclease technologies.'

SureGuide kits provide the easiest and fastest integrated solution for scientists looking to benefit from the advances in CRISPR/Cas technology by adding this technique to their workflow. SureGuide is the first in a series of products from Agilent that will continue to enable new applications in genome editing and engineering. It will be followed by the release of other products specifically targeted to synthetic biology and functional genomics.

Click here to learn more about Agilent's SureGuide family of products.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company's 20,600 employees serve customers in more than 100 countries. Agilent had revenues of $6.8 billion in fiscal 2013. Information about Agilent is available at

In September 2013, Agilent announced plans to separate into two publicly traded companies through a tax-free spinoff of its electronic measurement business. On Aug. 1, 2014, the company's electronic measurement business began operating as Keysight Technologies, Inc., a wholly owned subsidiary. The separation is expected to be completed in early November 2014.

Customer comments

No comments were found for Agilent Technologies Introduces Tools for Next-Generation Genome Engineering. Be the first to comment!